Navigation Links
Halozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17
Date:8/12/2011

SAN DIEGO, Aug. 12, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that management will be presenting at the Wedbush 2011 Life Sciences Conference in New York. The presentation is scheduled for Wednesday, August 17 at 9:10 a.m. EDT (6:10 a.m. PDT). To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the company's Web site at www.halozyme.com. A replay will be available for 90 days after the event.

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze(TM) technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche, Baxter, ViroPharma and Intrexon to apply Enhanze technology to therapeutic biologics including Herceptin®, MabThera®, immunoglobulin, Cinryze® and recombinant human alpha 1-antitrypsin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.

Halozyme Contact
Kurt Gustafson
Chief Financial Officer
(858) 704-8272
kgustafson@halozyme.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozymes Ultrafast Insulin Demonstrates Reduced Variability of Insulin Absorption for Type 1 Diabetes Patients Using Insulin Pumps
2. Halozyme and Intrexon Announce Collaboration to Develop First Subcutaneous Recombinant Alpha 1-Antitrypsin Replacement Therapy
3. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
4. ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor
5. Halozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12
6. Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6
7. Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
8. Halozyme Therapeutics to Host Fourth Quarter and 2010 Financial Results Conference Call on March 11
9. Halozyme Therapeutics to Present at J.P. Morgan Healthcare Conference on January 12
10. Halozyme Therapeutics Realigns Management
11. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... , June 8, 2017  Less than a month ... more than 200,000 companies, including hospital networks, in over ... as one of the largest online extortion attempts ever ... healthcare market, it is imperative that providers understand where ... data from this — and many other very real ...
(Date:6/7/2017)... Iowa , June 6, 2017  Diplomat Specialty Infusion Group, ... sterile compounding environment to its Iowa location. ... Urbandale now features an ISO 7 cleanroom—the standard ... controlled environment with a low level of pollutants. ... more IV nutrition consumers and better serve our Iowa ...
(Date:6/1/2017)... 1, 2017 Nutriceutical Holdings (NH), parent company ... (VRS), and KD Pharma Group have decided to join ... KD Pharma Group. KD Pharma Group will become the ... acquire the entire company. "We believe we ... committed to growing the NH companies by providing us ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... ... All-Star Insurance, a family managed agency that offers insurance management assistance and personal ... of a new charity drive to benefit women in the area diagnosed with breast ... estimated 252, 710 new cases of invasive or high risk breast cancer will be ...
(Date:6/22/2017)... ... 2017 , ... Plastic Surgery Associates is proud to report that founding surgeon, ... research and information firm, Castle Connolly, releases their list of the most notable and ... 3rd time that Dr. Canales has been recognized by Castle Connolly. , ...
(Date:6/22/2017)... ... 2017 , ... Despite its pervasiveness, many physicians are unfamiliar with how best ... with clinical practice. Now, however, a timely review has been published in the ... etiology of NeuP and educating preclinical scientists on its diagnosis and choice of treatment. ...
(Date:6/22/2017)... ... June 23, 2017 , ... Rise Against Hunger ... June 21, 2017, at the Emeryville Center of Community Life. More than 374 ... world. , Rise Against Hunger (formerly Stop Hunger Now) meal packaging events are ...
(Date:6/20/2017)... , ... June 20, 2017 , ... After months of negotiations, FaceCradle USA is proud ... on Wednesday, June 21. , “Introducing our product on QVC is something we all ... promote our travel pillow to more than 90 million homes in the United States,” said ...
Breaking Medicine News(10 mins):